Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary) ; Psilocybin
Indications Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia
Focus Therapeutic Use
Sponsors Mindmed

30 Nov 2021 Results published in the Mind Medicine (MindMed) Media Release
07 Nov 2021 Primary endpoint (5 dimensions of altered state of consciousness (5D-ASC) profile total score) has been met, as per results published in the Clinical Pharmacology and Therapeutics.
07 Nov 2021 Results assessing the response to psilocybin (25 mg) in healthy subjects after pretreatment with escitalopram or placebo, published in the Clinical Pharmacology and Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com